These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32191306)

  • 1. Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals.
    Lepore L; Fabrizio C; Bavaro DF; Milano E; Volpe A; Lagioia A; Angarano G; Saracino A; Monno L
    J Antimicrob Chemother; 2020 Jun; 75(6):1580-1587. PubMed ID: 32191306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir.
    Bouba Y; Berno G; Fabeni L; Carioti L; Salpini R; Aquaro S; Svicher V; Perno CF; Ceccherini-Silberstein F; Santoro MM
    J Antimicrob Chemother; 2020 Jul; 75(7):1778-1786. PubMed ID: 32160290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
    Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
    J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
    Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
    J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
    Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
    J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.
    Gartland M; Arnoult E; Foley BT; Lataillade M; Ackerman P; Llamoso C; Krystal M
    J Antimicrob Chemother; 2021 Oct; 76(11):2958-2964. PubMed ID: 34297843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate.
    Wensel D; Gartland M; Beloor J; Shetty KN; Wolf J; Stewart E; Clark A; Tenorio A; Krystal M
    Antiviral Res; 2024 Sep; 229():105953. PubMed ID: 38960100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
    Fofana DB; Charpentier C; Maïga AI; Lambert-Niclot S; Sayon S; Désiré N; Simon A; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG; Soulié C
    J Antimicrob Chemother; 2015 Jan; 70(1):130-5. PubMed ID: 25270328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Gartland M; Cahn P; DeJesus E; Diaz RS; Grossberg R; Kozal M; Kumar P; Molina JM; Mendo Urbina F; Wang M; Du F; Chabria S; Clark A; Garside L; Krystal M; Mannino F; Pierce A; Ackerman P; Lataillade M
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0175121. PubMed ID: 35502922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
    Soulié C; Lambert-Niclot S; Fofana DB; Fourati S; Ait-Arkoub Z; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1243-5. PubMed ID: 23396856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.
    Saladini F; Giannini A; Giammarino F; Maggiolo F; Vichi F; Corbelli GM; Galli A; Bigoloni A; Poli A; Santoro MM; Zazzi M; Castagna A
    J Antimicrob Chemother; 2020 Sep; 75(9):2547-2553. PubMed ID: 32464638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.
    Hoffman NG; Seillier-Moiseiwitsch F; Ahn J; Walker JM; Swanstrom R
    J Virol; 2002 Apr; 76(8):3852-64. PubMed ID: 11907225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
    Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
    Antiviral Res; 2024 Aug; 228():105957. PubMed ID: 38971430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
    Grant PM; Kozal MJ
    Curr Opin HIV AIDS; 2022 Jan; 17(1):32-35. PubMed ID: 34871189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
    Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
    N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical correlation of nonconservative substitutions of HIV gp41 variable amino acid residues with the R5X4 HIV-1 phenotype.
    Pacheco-Martínez E; Figueroa-Medina E; Villarreal C; Cocho G; Medina-Franco JL; Méndez-Lucio O; Huerta L
    Virol J; 2016 Feb; 13():28. PubMed ID: 26879054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
    Gartland M; Zhou N; Stewart E; Pierce A; Clark A; Ackerman P; Llamoso C; Lataillade M; Krystal M
    J Antimicrob Chemother; 2021 Feb; 76(3):648-652. PubMed ID: 33241285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.